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ABSTRACT B3 is a monoclonal antibody that reacts with
a carbohydrate epitope present on a variety of proteins located
on the surface of many cancer cells and a limited number of
normal tissues. We evaluated the cytotoxic activity of immu-
notoxins composed of monoclonal antibody B3 coupled to
native Pseudomonas exotoxin (PE) or two recombinant forms of
Pseudomonas exotoxin, PEArW or LysPE40, a form ofPE with
a deletion of the cell binding domain. All three conjugates were
cytotoxic to human cell lines expressing the B3 antigen on their
surface. The survival of each of the three immunotoxins in the
circulation of mice was determined after administering the
immunotoxin i.v. The half-life in blood of B3-PE and B3-
PEArO7 was 20 hr, whereas the half-life of B3-LysPE40 was 4
hr. The short half-life ofB3-LysPE40 may be due to the absence
of domain I of PE. To determine the therapeutic effects of the
three immunotoxins, they were given intraperitoneally to nude
mice bearing subcutaneous A431 tumors. All three inmuno-
toxins caused complete regression of 50-mm3 tumors with no
toxic effects to the animals at therapeutic doses. Furthermore,
substantial regression was also noted with much larger tumors.
Our data indicate that the monoclonal antibody B3, when
coupled to PE or recombinant forms of PE, may be useful for
the treatment oftumors expressing B3 antigen. The therapeutic
window was largest with B3-LysPE40, which can be adminis-
tered in higher doses because it lacks sequences in domain I of
PE that enable PE to bind to nontarget cells.
Immunotoxins are potent cell killing agents that are emerging
as chemotherapeutic agents for the treatment of cancer,
acquired immune deficiency syndrome (AIDS), and some
immunological disorders (1-5). We have been developing an
alternate approach to conventional cancer chemotherapy
using immunotoxins made from Pseudomonas exotoxin (PE)
or genetically modified forms of PE coupled to antibodies
reactive with antigens present on the surface of solid tumors.
Initially, we showed that immunotoxins containing antibod-
ies to the human transferrin receptor were very effective
cell-killing agents in vitro and in vivo (6). However, these
agents have limited clinical utility, because they react with
many vital normal human tissues. We isolated a monoclonal
antibody reactive with many ovarian cancers and coupled
this antibody (OVB3) to PE. This immunotoxin, OVB3-PE,
was shown to kill human ovarian cancer cells in culture and
to prolong the life of nude mice bearing human ovarian
tumors (7). However, this agent was poorly tolerated in a
phase I trial in women because ofthe reactivity ofOVB3 with
some cells in normal human cerebellum (unpublished data).
Therefore, it was necessary to obtain a more tumor-specific
antibody with no cross reactivity to vital human tissues.
We have isolated a murine monoclonal antibody termed
B3, that shows strong reactivity with many mucin-producing
tumors of the ovary, stomach, and colon, as well as strong
reactivity with nonmucinous carcinomas of the colon and
stomach (I.P., L.H.P., E. T. Lovelace, M. G. Gallo, A. V.
Rutherford, J. L. Magnani, and M.C.W., unpublished data).
Peroxidase immunohistochemistry using frozen sections of
normal tissue demonstrated that B3 reacts with cells of the
stomach, with the differentiated cell layer of the esophagus,
with the epithelia of the tonsil, trachea, and urinary bladder,
and with small bowel mucin. Similar reactivity was found in
normal monkey tissues. Biochemical studies have shown that
B3 reacts with a carbohydrate epitope present on many
different cell surface proteins (unpublished data). The tissue
and tumor reactivity of B3 is quite similar to that of mono-
clonal antibody BR96 (8). However, several differences in
reactivity exist that show that B3 reacts with an epitope
different from that of BR96.
PE is a 66-kDa protein composed of three domains: an
amino-terminal cell receptor binding domain (domain I), a
middle translocation domain (domain II)+ and a carboxyl-
terminal activity domain (domain III). Dmain III catalyzes
the ADP-ribosylation and inactivation of elongation factor 2,
which inhibits protein synthesis and leads to cell death (9, 10).
Immunotoxins made with native PE are often very active but
can produce liver toxicity due to the presence of domain I of
PE (amino acids 1-252), which binds to PE receptors found
on many normal cells. To overcome liver toxicity, various
recombinant forms ofPE have been made in Escherichia coli.
Lysine-57 (domain I) was shown to be involved in the cellular
binding of PE (11), and when mutated to arginine, its cyto-
toxic activity on mouse L929 cells fell about 5-fold (unpub-
lished data). LysPE40 is a 40-kDa recombinant form of PE
that lacks all ofdomain I and contains an extra lysine residue
near its amino end to facilitate coupling to antibodies (6).
The current report describes the characteristics and activ-
ity of three immunotoxins in which B3 was coupled to native
PE to make B3-PE, to PEAm7 to make B3-PEAxW7, or to
LysPE40 to make B3-LysPE40.
MATERIALS AND METHODS
Monodonal Antibody B3. The isolation and characteriza-
tion of B3 will be described in detail elsewhere. Briefly,
BALB/c mice were tolerized with normal human kidney
membranes and immunized with trypsin-treated MCF-7
cells. Spleens from immunized mice were removed and the
suspended cells were fused with AG8 mouse myeloma cells.
The antibodies produced by the resulting clones were
screened 2 weeks later using rhodamine indirect immuno-
fluorescence on living MCF-7 cells. Screening was carried
out using a ScreenFast (Life Technologies, Gaithersburg,
MD) large-scale screening chamber (12). Selected clones
were secondarily screened using peroxidase immunohis-
tochemistry on cryostat sections of human tumors and nor-
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Table 1. Cytotoxicity of B3-PE, B3-PEAr7, and B3-Lys PE40
on various tumnor cell lines
ID50, ng/ml
Cancer B3- B3- B3- MOPC-
type Cell line PE PEAM57 LysPE40 PE
Epidermnoid
vulva A431 0.1 0.2 1.1 >1000
Breast MCF-7 0.1 0.2 0.9 >1000
HTB-19 25 30 ND ND
HTB-30 30 30 ND ND
CRL-1500 20 20 100 >1000
Gastric HTB103 4 10 100 >1000
CRL 1793 0.1 0.2 1.0 >1000
Prostate LnCAP 9 12 85 >1000
PC-3 30 35 275 >1000
Bladder RT4 8 10 ND ND
mal tissues. One clone was retained that reacted with human
colon cancers and gastric cancers but not with normal human
liver, kidney, or colon. It was doubly subcloned and its
isotype was determined to be IgG1K. The antibody was
purified from serum-free culture medium by ammonium
sulfate precipitation and chromatography on a TSK-250
gel-filtration column (21.5 x 600 mm). Its purity was estab-
lished by SDS/PAGE. Monoclonal antibody MOPC-21 is a
mouse myeloma antibody (IgG1) with no known reactivity
with mouse or human tissues and was purchased from Sigma.
PE, PEA'O', and LysPE40. PE purified from the culture
medium of Pseudomonas aeruginosa was purchased from
Swiss Serum (Berne, Switzerland). PEArg7 was prepared
from the periplasm of E. coli as described for other PE
constructs using plasmid pJY557R (Y. Jinno, V. Chaudhary,
and I.P., unpublished data). LysPE40 was prepared from the
medium as described (6).
Construction of Immunocohjugates. PE, PEArg57, or
LysPE40 at 5-10 mg/ml in 0.2 M sodium phosphate (pH 7.0)
containing 1 mM EDTA was mixed with a 3-fold molar excess
of succinimidyl-4-(N-maleimidomethyl)cyclohexane-l-
carboxylate and incubated at room temperature for 30 min.
Protein was separated from the unreacted cross-linker on a
PD10 column. Monoclonal antibody (B3 or MOPC-21) at
5-10 mg/ml was mixed with a 3-fold molar excess of 2-imi-
nothiolane hydrochloride in 0.2M sodium phosphate (pH 8.0)
containing 1 mM EDTA and incubated at 37°C for 1 hr. The
derivatized antibody was separated from the reactants on a
PD10 column. Derivatized antibody and PE, PEW', or
LysPE40 were mixed and incubated at room temperature for
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FIG. 1. A431 at 5 x 105 cells per 1.5 ml was incubated with
various concentrations of free antibody (o) or immunotoxins BE-
PEArg57 (0) or B3-LysPE40 (o), and their competition for the
binding of 1251-labeled B3 was measured.
16-20 hr. Immunotoxin was then purified by successive
chromatography on MonoQ and TSK 250 columns (13).
SDS/PAGE was done as described (13). The major immu-
notoxin peak consisted ofa 1:1 conjugate of antibody and PE
or PEAIg57 or LysPE40. Yields were in the range of 10-15%
of the starting materials.
Protein Synthesis Assay. Inhibition ofprotein synthesis was
used to measure the activity ofeach immunotoxin on various
cell lines. Immunotoxins were diluted with 0.2% human
serum albumin in phosphate-buffered saline (PBS) prior to
addition to cells. Cells were seeded at 1 x 105 cells per ml in
24-well plates or 96-well plates 24 hr prior to the addition of
immunotoxin, incubated at 37°C for 24 hr, and then assayed
for incorporation of [3H]leucine (New England Nuclear;
specific activity, 1408 Ci/nmol; 1 Ci = 37 GBq) as described
(13). The mean values of triplicates were expressed as
percentage of controls that did not receive immunotoxin.
Antibody Binding Assay. B3 was iodinated by the lacto-
peroxidase method and purified by gel filtration on a PD1O
column. MCF-7 and A431 cells were seeded at 5 x 105 cells
per 1.5 ml in 12-well plates 24 hr prior to the assay. Cells were
washed with ice-cold phosphate-buffered saline containing
bovine serum albumin (2 mg/ml). Initial experiments deter-
mined that the binding of 125I-labeled B3 (specific activity, 0.014
AtCi/ng) to A431 and MCF-7 cells reached equilibrium at 2 hr.
In the competition studies, various concentrations of free
antibody or B3-PEAW7 or B3-LysPE40 were added to these
cells and their ability to compete for the binding of 2-5I-labeled
B3 was determined.
Assay of Blood Levels of B3-PE, B3-PE'. 5, and B3-
LysPE40 in Mice. Four- to 6-week-old (19-20 g) female
BALB/c mice or immunodeficient (nu/nu) mice bearing
A431 subcutaneous tumors were injected with 1 ,ug ofB3-PE,
B3-PEAW7, or 20 tg of B3-LysPE40 in the tail vein. Blood
was drawn at 2 min, 10 min, 1 hr, 4 hr, 8 hr, 12 hr, 24 hr, 48
hr, and 72 hr, and the level of the immunotoxin was assayed
by incubating serum with A431 cells and measuring its ability
to inhibit protein synthesis. A standard curve was made for
each immunotoxin.
Anti-Tumor Activity ofB3-PE, B3-PEAW7, and B3-LysPE40
in Nude Mice Bearing a Human Epidermoid Carcinoma. A431
cells (3 x 106 cells) were injected subcutaneously on day 0
into female nude mice (4-6 weeks old, 18-20 g). Tumors
about 5 mm x 5 mm in size developed in all mice by day 5.
Treatment ofmice with B3-PE, B3-PEAW7, and B3-LysPE40
was started on either day 1, day 4, or day 7 after tumor
implantation. Each treatment group consisted of five or six
00080
0
C.)
01-1
0.01 0.1 1.10o.0
B3 or B3 conjugate, ng/ml
FIG. 2. Inhibition of protein synthesis in A431 cells by B3
conjugates. Immunotoxins were added to the cells in the absence (v,
A, *) or in the presence (o, A, o) of excess B3 (25 pyg/ml) for 18-24
hr at 37°C. * and o, B3-PE; A and A, B3-PEAW7; * and o,
B3-LysPE40.
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FIG. 3. Blood levels of B3-PE and B3-PEAW7 (A) and B3-LysPE40 (B). BALB/c mice or nude mice bearing A431 tumor (50 mm3) were injected
iLv. with 1 l&g of B3-PE (a), 1 j.tg of B3-PEW7 (e), or 20 j.Ag of B3-LysPE40 (0). Immunotoxin levels were measured in serum as indicated. Results
are the average of two experiments and expressed as percent of the immunotoxin present in the serum 2 min after injection and in ng/ml.
animals. Tumors were measured with a caliper every 4 days
and the volume of the tumor was calculated by using the
following formula: tumor volume (in mm') = length x
(width)2 x 0.4. All statistical comparisons were made'using
the Wilcoxon rank sum test.
RESULTS
Monoclonal antibody B3 was selected because of its reac-
tivity with many colon, gastric, breast, and ovarian tumors.
To determine if B3 could deliver toxins to target cells and kill
these cells, immunotoxins were prepared consisting of B3
coupled to three forms of PE. B3-PE is an immunotoxin in
which B3 is coupled to native PE. B3-PEArI7 -is an immu-
notoxin in which B3 is coupled to a mutant form of PE in
which lysine-57 is changed to arginine. This mutation de-
creases the ability of PE to bind to the PE receptor found on
almost all cells; PEAI7 is about 5-fold less toxic than PE to
3T3 cells and to mice (unpublished data). Finally, B3 was
coupled to LysPE40, a mutant form of PE that lacks domain
I and is, therefore, much less toxic to cultured cells and to
mice (6).
The activities ofB3-PE, B3-PEArW7, and B3-LysPE40 were
tested on a variety of human adenocarcinoma cell lines as
well as on the epidermoid carcinoma cell line A431 (Table 1).
The three immunotoxins were found to be active in most of
A _ _ _ _ _ _ _ _ _ _ _ _
1.0-
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E
-0.6-
N
0
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the cell lines tested; however, they were especially active on
three cell lines: the A431 epidermoid carcinoma cell line, the
MCF-7 breast carcinoma cell line, and the CRL 1793 gastric
carcinoma cell line. On A431 and MCF-7 cells, conjugates
made with both PE, PEA197, anid LysPE4O were extremely
active with ID" values ranging from 0.2 to 1 ng/ml. The
cytotoxic effect of these immunotoxins was shown to be
specific because MOPC-PE, an immunotoxin made with an
antibody that does not react with human cells, had no
cytotoxic activity even at 1000 ng/ml.
To determine the relative binding activity of two of the
immunotoxins, the native B3 antibody was iodinated and the
ability of B3-PEAW7 and B3-LysPE40 to displace the iodi-
nated antibody was determined and compared with the ability
of native unlabeled antibody to displace the 1251-labeled
antibody. As shown in Fig. 1, B3-P 7and B3-LysPE4O
displaced 125I-labeled B3 in a similar manner with 50%1
inhibition occurring at =-100 pM. Based on the finding that
50% inhibition of binding by B3 occurred at 35 pM, the
immunotoxins bind to cells about 20% as well as native
antibodies.
Fig. 2 shows the cytotoxic activity of the three B3 conju-
gates on A431 cells. The activities of B3-PE and B3-PEA~~
are very similar and B3-LysPE40 is somewhat less active.
The cytotoxic activities of all three immunotoxins are spe-
B
Time, days
FIG. 4. Effect of B3-PE (A) and B3-PEA07 (B) on the growth of A431 tumors in nude mice. Mice were injected with 3 x 106 A431 cells and
treated iLp. with B3-PE or B3-PEAMs7. Animals were given three 0.75-j.ug doses on days 4, 6, and 8 (m) or on days 7, 9, 11, 13, and 15 (*); control
group received PBS (0). Error bars are SD.
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FIG. 5. Effect of B3-PE (A) and B3-PEArO7 (B) on the growth of A431 tumors in nude mice. Animals were injected with 0.25 ,ug (n), 0.5j&g (o), or 0.75 ug (A) of B3-PEA57; control group (e) was given PBS. Error bars are SD.
cific, because they are completely eliminated by the addition
of excess B3 (25 Ag/ml).
The potent cytotoxic activity of the immunotoxins con-
taining B3 suggested that these agents might be effective
against tumors bearing the B3 antigen. To determine the
blood levels that could be achieved in these mice and the
duration that the immunotoxin would be present in the blood,
1 Lg of B3-PE, 1 Ag of B3-PEAr 7, or 20 ,ug of B3-LysPE4O
were administered to groups of mice. The immunotoxins
were given intravenously and serum samples were collected
beginning 2 min after the i.v. injection. The data in Fig. 3
show the blood levels of the three immunotoxins. B3-PE and
B3-PEArg57 decayed slowly with an apparent half-life of about
20 hr. B3-LysPE40 decayed more quickly with an apparent
half-life of about 4 hr.
Because the immunotoxins were present at substantial
concentrations for many hours, it seemed possible that they
might exert an anti-tumor effect. Therefore, the anti-tumor
activity of the immunotoxin was assessed in nude mice
bearing A431 human epidermoid cancer cells. To do this, 3 x
106 cells were injected subcutaneously on day 0. Treatment
was started on day 4 with either PBS or immunotoxin
dissolved in PBS. On day 4, the tumors measured about 5 x
5 mm and were about 50 mm3 in size. As shown in Fig. 4, in
animals that were given three doses of 0.75 Mg of B3-PE or
B3-PEAI57 on days 4, 6, and 8, the tumors completely
disappeared and remained undetectable for 3 months. The
two groups, control and treated, were compared at each time
point using the Wilcoxon rank test. Beginning on day 12 there
was a significant anti-tumor effect evident with both B3-PE
and B3-PEArg57 (P2 < 0.005). In the animals treated on days
7, 9, and 11, the tumors stopped growing, regressed some-
what, and then resumed their growth. In animals treated on
days 7, 9, 11, 13, and 15, the tumors regressed substantially
leaving a hemorrhagic mass with a rim of living cancer cells.
The mass then remained at about the same size for 24 days
(P2 = 0.009).
Fig. 5 A and B shows the effect of B3-PE and B3-PEArO7,
respectively, on the growth of A431 tumors in nude mice at
various dose levels. Mice were injected with 3 x 106 cells
subcutaneously on day 0 and treatment with B3-PE or
B3-PEArg57 was started on day 4 by administering 0.75 Mug, 0.5
Mug, and 0.25 ug every other day. At a dose level of 0.25 Mg
or 0.5 Mg, the tumors disappeared almost completely after
treatment but resumed their growth 3-4 weeks later. Animals
treated with 0.75 Mug showed no evidence of tumor after 3
months (P2 < 0.0001).
To determine the anti-tumor activity of B3-LysPE40,
groups of animals bearing A431 tumors were treated every
other day i.p. with the immunoconjugate at dose levels of 2.5,
10, and 20 ug. Treatment was initiated on day 4. As shown
in Fig. 6, at the dose level of 20 ,g, complete remission ofthe
tumor was observed that lasted for at least 3 months (P2 <
0.0001). With 10 Mg and 2.5 ug, only partial remissions were
observed.
DISCUSSION
In this study, we have shown that immunotoxins made with
B3, a monoclonal antibody that reacts with many human
carcinomas, kill cell lines reacting with the antibody and
cause regression of a human epidermoid carcinoma. In ad-
dition, we have found that B3-PE causes regression of the
MCF-7 breast carcinoma (unpublished data). B3 was coupled
to several forms of PE. The toxicity in animals of immuno-
toxins made with native PE is mainly due to the binding of
domain I of PE to liver cells (9). To minimize the toxic effect
of PE due to its nonspecific binding, we made immunocon-jugates with two recombinant forms of PE, PEA`97 and
LysPE40. PEAr57 is approximately 5-fold less toxic to murine
L929 cells than native PE; it is also less toxic to mice than
native PE. The anti-tumor activities ofthe immunoconjugates
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FIG. 6. Effect of B3-LysPE40 on the growth of A431 tumors in
nude mice. Animals were injected with 3 x 106 cells on day 0.
Therapy was initiated on day 4, three doses of 2.5 gg i.p. every other
day (o), 10 ,ug (A), and 20 ,ug (o); control group received PBS (-).
Error bars are SD.
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B3-PE and B3-PEAr57 in vitro and in mice are very similar
(Fig. 1). However, the LD50 values of the two conjugates in
mice showed only small differences. The single-dose LD50 is
2.5 ,ug for B3-PE and 3.5 1Lg for B3-PEA 57. Although not
significant, these findings suggest that this recombinant form
of PE may have a small advantage over native PE for use in
immunoconjugates due to its slightly lower toxicity. In con-
trast, LysPE40 appears to be a superior molecule for conju-
gation with monoclonal antibodies. B3-LysPE40 has no de-
tectable cytotoxicity against cultured cells to which the
antibody does not bind. Furthermore, 20 ,g of B3-LysPE40
has a remarkable antitumor activity when injected three to
five times. The single-dose LD50 of the B3-LysPE40 is about
200 ug.
When administered i.v. in mice at a dose of 1 ,tg, B3-PE
and B3AWr7 have half-lives of 20 hr; this is to be compared
with B3-LysPE40, which has a half-life of only 4 hr. The
absence of domain I of PE not only has an effect on the
binding ofPE to cells (9) but also shortens its half-life in mice.
The biochemical basis ofthis difference in half-life remains to
be determined.
All three conjugates produced complete regression of
actively growing solid tumors using doses that were nontoxic
to animals. When the tumors were allowed to grow to a larger
size, four doses of the immunotoxin decreased the tumor
size, the mass became hemorrhagic, and the overlying skin
became necrotic probably due to infiltration ofthe tumor into
the skin. Because of this skin necrosis leading to potential
infection in these immunodeficient animals, further doses
could not be administered to determine if these tumors could
also be completely eliminated.
In summary, B3 is a monoclonal antibody that shows
strong reactivity with many solid tumors, including mucinous
and nonmucinous adenocarcinomas. Its limited reactivity
with normal human tissues may make it useful for targeted
therapy in humans. Because B3 reacts with monkey tissues
in a manner similar to that of human tissues, it should be
possible to determine if an immunotoxin composed ofB3 and
one or more forms ofPE has properties that indicate it should
be evaluated in patients with cancer.
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